A Phase II Trial of Cisplatinum, Paclitaxel, and Sintilimab Induction Therapy Followed by De-escalation Radiotherapy for Patients With Postoperative Locally Advanced Head and Neck Squamous Cell Carcinoma
Latest Information Update: 29 Jul 2022
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Sintilimab (Primary)
- Indications Carcinoma; Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms iCSDeR
Most Recent Events
- 29 Jul 2022 New trial record